Medical Treatment of Pituitary Adenomas: A Celebration of Endocrinology (and Oncology)!

Horm Metab Res 2020; 52(01): 7
DOI: 10.1055/a-1085-3562

Editorial

Constantine A. Stratakis

¹Medical Genetics, Pediatrics, Pediatric Endocrinology, Bethesda, USA

References
1 Spark RF, Dickstein G.. Bromocriptine and endocrine disorders. Ann Intern Med 1979; 90: 949-956
2 Hertz R, Ross GT, Lipsett MB.. Primary chemotherapy of nonmetastatic trophoblastic disease in women. Am J Obstet Gynecol 1963; 86: 808-814
3 Gheorghiu ML, Negreanu F, Fleseriu M.. Updates in the medical treatment of pituitary adenomas. Horm Metab Res. 2020; 52: 8-24
4 Xekouki P, Brennand A, Whitelaw B. et al. The 3PAs: An update on the association of pheochromocytomas, paragangliomas, and pituitary tumors. Horm Metab Res 2019; 51: 419-436
5 Petersenn S.. Management of aggressive pituitary tumors – a 2019 update. Horm Metab Res 2019; 51: 755-764
6 Polidoro MA, Rotondi S, Morace R. et al. Expression of peroxisome proliferator-activated receptor alpha (PPARα) in non-somatotroph pituitary tumours and the effects of PPARα agonists on MMQ cells. Horm Metab Res 2018; 50: 640-647
7 Feng Y, Mao ZG, Wang X. et al. MicroRNAs and target genes in pituitary adenomas. Horm Metab Res 2018; 50: 179-192